Tag Archives: Novartis’ Ultibro® Breezhaler®

New analyses confirm Novartis’ Ultibro® Breezhaler® more effective option for patients at risk of COPD flare-ups

Ultibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered patients’ need for rescue medication and had improved benefit-risk profile compared to Seretide, with … Read the full press release